Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9629049 | 0.82 | GAA (0.46) | GAANPC1HPGDRAB9A | |
| SCHEMBL6967216 | 0.76 | POLB (0.42) | GAAHPGD | |
| SCHEMBL1379363 | 0.75 | NPC1 (0.52) | GAANPC1HPGDRAB9A | |
| SCHEMBL6971704 | 0.74 | GAA (0.35) | GAANPC1HPGDRAB9A | |
| SCHEMBL9839963 | 0.74 | EPHX1 (0.39) | GAA | |
| SCHEMBL6965037 | 0.73 | POLB (0.44) | GAAHPGD | |
| SCHEMBL7283222 | 0.72 | — | — | |
| SCHEMBL24484317 | 0.71 | ALDH1A1 (0.52) | GAANPC1RAB9A | |
| SCHEMBL5914768 | 0.71 | MEN1 (0.43) | GAANPC1HPGDRAB9A | |
| SCHEMBL20832803 | 0.71 | TPMT (0.41) | GAANPC1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147371-A1 | OXADIAZOLINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | US | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| US-4995898-A | Imidazole compounds and biocidal composition comprising the same for controlling harmful organisms | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1991-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147371-A1 | OXADIAZOLINE DERIVATIVES | DDT, FOXO3, PDCD4 | GAA 1749/4885NPC1 3922/4885HPGD 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.